Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Phase 1

3(60.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 1(3)

Phase 2(1)

Phase 3(1)

Loading network data...

Showing 5 of 5 trials

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Role: collaborator

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Role: lead

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Role: collaborator

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

Role: collaborator

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Role: lead

All 5 trials loaded